3-bromo-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine | 437613-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-bromo-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine
• CAS: 437613-01-9
• 化学式: C₁₈H₁₇BrFN₃
• 分子量: 374.255
• InChiKey: JPCHUGJACCMNKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 、 肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 N-cyclopentyl-2-(4-fluorophenyl)-3-(2-hydrazino-4-pyridinyl)pyrazolo[1,5-a]pyridin-7-amine
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyridine antiherpetics: Effects of the C3 substituent on antiviral activity

  摘要：

  A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the hetero-atom basicity and orientation of the group at C3. These results in combination with previous studies have served to further elaborate the minimal pharmacophore required for potency of this novel series of antiviral agents. During the course of these studies, several novel synthetic approaches were developed and are described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.058
• 作为产物：
  描述：

  7-氯-2-(4-氟苯基)吡唑并[1,5-a]吡啶 在 palladium diacetate 、 N-溴代丁二酰亚胺(NBS) 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 3-bromo-N-cyclopentyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine
  参考文献：
  名称：

  吡唑并[1,5- a ]吡啶：一类新型抗疱疹药的合成方法

  摘要：

  描述了新型的7-氨基-3-嘧啶基-吡唑并[1，5- a ]吡啶抗疱疹化合物的合成。设计合成方法以允许在吡唑并[1，5- a ]吡啶的C-3和C-7位置附近进行快速类似物合成。通过叠氮基重排产生的7-氯吡唑并[1,5- a ]吡啶D是关键的组成部分。描述了用于构建C-3嘧啶的两种互补方法。这些方法包括开发利用炔基酮或烯酮的新型环化反应，以得到高度取代的嘧啶。概述的策略促进了C-3或C-7位置的后期操作，为快速模拟合成提供了灵活性。

  DOI：

  10.1016/j.tet.2003.02.003

文献信息

• Theraopeutic compounds
  申请人：Boyd Leslie F

  公开号：US20050049259A1

  公开（公告）日：2005-03-03

  The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了化合物I的配方，包括含有它们的药物组成、制备它们的过程以及它们作为药物代理的用途。
• Pyrazolopyridinyl pyrimidine therapeutic compounds
  申请人：SmithKline Beecham Corporation

  公开号：US07163940B2

  公开（公告）日：2007-01-16

  The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了式(I)的化合物：其中所有变量如此处所定义，包含这些化合物的药物组合物，制备这些化合物的过程以及它们作为药物剂的用途。
• Pyrazolopyridinyl pyridine
  申请人：Boyd F. Leslie

  公开号：US20070287721A1

  公开（公告）日：2007-12-13

  The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供公式（I）的化合物：包含它们的药物组合物，制备它们的过程以及它们作为药物制剂的用途。
• PYRAZOLOPYRIDINE DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1377573B1

  公开（公告）日：2005-07-27
• Pyrazolo[1,5-a]pyridine antiherpetics: Effects of the C3 substituent on antiviral activity
  作者：Brian A. Johns、Kristjan S. Gudmundsson、Scott H. Allen

  DOI：10.1016/j.bmcl.2007.02.058

  日期：2007.5

  A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the hetero-atom basicity and orientation of the group at C3. These results in combination with previous studies have served to further elaborate the minimal pharmacophore required for potency of this novel series of antiviral agents. During the course of these studies, several novel synthetic approaches were developed and are described. (c) 2007 Elsevier Ltd. All rights reserved.